Couple lied about cancer-detecting machine, then sold fake cure, feds say
A third person has been charged after authorities say they lied to patients about being able to detect and cure cancer.
Mary Blakley and Fred Blakley were each charged in January with several counts of mail fraud, wire fraud and conspiracy to violate the Food, Drug and Cosmetic Act. In a superseding indictment filed June 5, Janmarie Lanzo was charged with conspiracy to violate the Food, Drug and Cosmetic Act and defraud the Food and Drug Administration, according to court records and a June 17 news release from the U.S. Attorney's Office for the Eastern District of Pennsylvania.
McClatchy News reached out to attorneys for Mary Blakley, Fred Blakley and Janmarie Lanzo but did not immediately hear back.
Mary Blakley and Fred Blakley are accused of running a medical clinic business where they charged patients across the U.S. for 'full body scans,' according to prosecutors.
Lanzo was a business associate who worked at the clinics and sold products to patients, officials said.
Mary Blakley and Fred Blakley typically charged patients $300 for a scan by an ultrasound machine, officials said.
They told the patients that Mary Blakley invented a 'smart chip technology' that when added to the ultrasound machine, could detect 'a wide variety of human diseases and medical conditions, including cancers,' prosecutors said.
The couple and their employees told patients that this technology could 'treat and cure a wide range of human diseases, illnesses and conditions, including by: 'driving' a substance known as Aetheion into the body to kill cancer,' the indictment said.
'Based on the results of these 'full body scans,' the defendants falsely and fraudulently prescribed to their human clients various supplements, creams, and veterinary products,' officials said.
The three sold Aetheion, a cosmetic cream, to patients, according to the release. They also sold them fenbendazole, a veterinary antiparasitic, and told them it could treat cancer, officials said.
Fenbendazole is not approved for human use by the FDA, court records said. It is typically used to treat worms in animals.
The three also prescribed ProArgi9+ and told patients it was used to treat multiple sclerosis and diabetes, court records said. ProArgi9+ is not approved by the FDA to treat diseases and is used as a dietary supplement.
Mary Blakley carried out the scheme by lying about having a Ph.D. in radiation nuclear physics, having dual U.S./Swedish citizenship and working as a cancer specialist and part of a research team that developed fenbendazole, according to court records.
If convicted, Mary Blakley and Fred Blakley face 165 years in prison and Lanzo faces five years in prison.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Vistagen reports FY25 EPS ($1.67), two estimates ($1.74)
Reports FY25 revenue $486K vs. $1.06M last year. 'This was a defining year for Vistagen (VTGN), marked by significant progress in our registration-directed PALISADE program for fasedienol in social anxiety disorder. With over 30 million U.S. adults affected by this serious and life-threatening disorder and no FDA-approved acute treatment, the need is urgent,' said Shawn Singh, President and Chief Executive Officer of Vistagen. 'The enthusiasm from both patients and physicians continues to motivate us as we advance toward our next significant milestone of topline data from our PALISADE-3 trial later this year. We are also continuing to advance the development of our other lead programs, itruvone for major depressive disorder and PH80 for menopausal hot flashes and additional women's health indications. With five novel pherine product candidates in our neuroscience pipeline targeting at least six high-need indications, we are energized by the road ahead and confident in our strategic position and potential to deliver meaningful value to patients and our shareholders.' Confident Investing Starts Here:
Newsweek
2 hours ago
- Newsweek
Nut Recall Map Shows Six States With New Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Retailer Meijer is recalling packages of Frederik's brand Dark Chocolate Almonds this week because they could potentially contain cashews, which are not disclosed on the packaging. Newsweek reached out to the company via email Tuesday night for comment. Why It Matters Numerous recalls have been initiated in 2025 due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA also warns that people with an allergy or severe sensitivity to cashew nuts potentially "run the risk of a serious or life-threatening allergic reaction if they consume the product." What To Know In the alert, the agency says that the recall includes the dark chocolate-covered almonds sold in stand-up pouches in Meijer stores, with sell by dates of May 7, 2026, and May 28, 2026. Additional 8-count 1.5-ounce multi-pack boxes with a sell by date of May 5, 2026, are also part of the recall, the FDA says. The almonds were sold in the following states: Michigan, Indiana, Illinois, Ohio, Kentucky and Wisconsin, according to the agency. The FDA alert also shows a chart listing the affected products, with corresponding UPC code numbers. There have been no reported illnesses related to the recall as of Monday, per the agency. What People Are Saying The FDA in the alert, in part, regarding the company: "About Meijer: Meijer is a privately owned, family-operated retailer that serves customers at more than 500 supercenters, grocery stores, neighborhood markets, and express locations throughout the Midwest." Continuing: "As the pioneer of the one-stop shopping concept, more than 70,000 Meijer team members work hard to deliver a friendly, seamless in-store and online shopping experience featuring an assortment of fresh foods, high-quality apparel, household essentials, and health and wellness products and services. Meijer is consistently recognized as a Great Place to Work and annually donates at least 6 percent of its profit to strengthen its communities. Additional information on the company can be found by visiting Link Disclaimer." What Happens Next Customers who have purchased the recalled chocolate-covered nuts are urged to return the product to a Meijer store for a refund, the FDA says. Those with additional questions may contact Meijer at 800-543-3704 from 7 a.m. to 1 a.m. ET every day. "Customers with questions or concerns about their health are encouraged to contact their primary care provider," the alert also notes.
WebMD
3 hours ago
- WebMD
More Adults Can Now Get Moderna's RSV Shot
June 17, 2025 – The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it. First approved in 2024 for people 60 or older, the mRESVIA vaccine protects against lower respiratory infections caused by RSV. This vaccine is now approved for adults ages 18 to 59 who have a higher risk of getting a serious RSV illness. RSV is a common virus that spreads easily in colder months through coughs, sneezes, or contact with contaminated surfaces. While it usually causes mild cold-like symptoms, it can be serious for babies and older adults. Vaccines and other preventive treatments offer the best protection against RSV. Moderna said the approval was supported by a study showing the vaccine is safe and works well for younger adults (ages 18 to 59) with medical conditions. Their immune response was just as strong as in older adults (60+), who had been studied earlier. All younger adults produced similar levels of protective antibodies against the two main types of RSV (RSV-A and RSV-B), showing the vaccine works well across at-risk adults of different ages. mRESVIA is an RNA vaccine that trains the body to make a harmless version of a protein used by the respiratory syncytial virus to enter human cells. This helps the immune system recognize the virus and build antibodies to protect against future infections. The vaccine does not contain RSV, so it cannot cause RSV illness. In clinical trials, the shot was generally well-tolerated. The most common side effects were mild and included pain where the needle went in, tiredness, headaches, muscle aches, joint pain, chills, nausea or vomiting, fever, and hives. Moderna plans to make mRESVIA available in the U.S. for the 2025-2026 respiratory virus season for high-risk adults ages 18 to 59 and all adults age 60 or older. Patients should tell their health care provider about any medical conditions they may have before getting the vaccine. This includes allergies, any serious reactions to vaccines in the past, current fever, any bleeding disorder or use of blood thinners, and a weakened immune system or use of medications that affect it. Patients should also say if they've already received another RSV vaccine or if they've ever fainted after getting a shot. There is a very small chance that mRESVIA can cause a severe allergic reaction, so patients may be asked to stay a while for observation after the shot.
